SHIJIAZHUANG CITY, China--(BUSINESS WIRE)--Lianhua Qingwen Capsules is a patent innovative traditional Chinese medicine developed by Yiling Pharmaceutical under the guidance of Luobing Theory of traditional Chinese medicine. It is developed by absorbing the valuable experience of traditional Chinese medicine in the treatment of cold and influenza, as well as the research experience drawn from modern anti-virus, antibacterial, and immune enhancement.
Studies have shown that Lianhua Qingwen capsules have the effects of broad-spectrum antiviral, bacteriostatic, antipyretic and antiphlogistic, relieving cough and decreasing sputum, and improving cellular immune function, etc. It can be used to treat influenza that is caused by heat-toxin attacking lungs, whose symptoms include fever, aversion to chills, muscle soreness, nasal congestion, runny nose, cough, headache, dry throat, sore throat, reddish tongue, yellowish tongue or tongue with greasy fur. For regular treatment of the novel coronavirus, Lianhua Qingwen capsules can be used to treat fever, cough and fatigue of lightly and ordinarily infected cases. Lianhua Qingwen Capsules has a wide range of applications. With its crucial role in major public health events and long-term and good reputation among the Chinese people, Lianhua Qingwen Capsules has been listed in recommendations many times by the Chinese authorities for cold and flu, such as the “Commonly Used Medicines by Chinese families in 2019-2020”.
Up to now, Lianhua Qingwen Capsules has obtained approval certificates from nearly 20 countries, including Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos, and has officially entered the Philippine market on November 23. Currently, the Philippine consumers can buy the medicine at the South Star Drug, Watsons and Mercury Drug.